HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.

AbstractBACKGROUND:
Medication-related interferences with measurements of catecholamines and their metabolites represent important causes of false-positive results during diagnosis of phaeochromocytomas and paragangliomas (PPGLs). Such interferences are less troublesome with measurements by liquid chromatography with tandem mass-spectrometry (LC-MS/MS) than by other methods, but can still present problems for some drugs. Levodopa, the precursor for dopamine used in the treatment of Parkinson's disease, represents one potentially interfering medication.
METHODS:
Plasma and urine samples, obtained from 20 Parkinsonian patients receiving levodopa, were analysed for concentrations of catecholamines and their O-methylated metabolites by LC-MS/MS. Results were compared with those from a group of 120 age-matched subjects and 18 patients with PPGLs.
RESULTS:
Plasma and urinary free and deconjugated (free + conjugated) methoxytyramine, as well as urinary dopamine, showed 22- to 148-fold higher (P < 0.0001) concentrations in patients receiving levodopa than in the reference group. In contrast, plasma normetanephrine, urinary noradrenaline and urinary free and deconjugated normetanephrine concentrations were unaffected. Plasma free metanephrine, urinary adrenaline and urinary free and deconjugated metanephrine all showed higher (P < 0.05) concentrations in Parkinsonian patients than the reference group, but this was only a problem for adrenaline. Similar to normetanephrine, plasma and urinary metanephrine remained below the 97.5 percentiles of the reference group in almost all Parkinsonian patients.
CONCLUSIONS:
These data establish that although levodopa treatment confounds identification of PPGLs that produce dopamine, the therapy is not a problem for use of LC-MS/MS measurements of plasma and urinary normetanephrine and metanephrine to diagnose more commonly encountered PPGLs that produce noradrenaline or adrenaline.
AuthorsGraeme Eisenhofer, Sebastian Brown, Mirko Peitzsch, Daniela Pelzel, Peter Lattke, Stephan Glöckner, Anthony Stell, Aleksander Prejbisz, Martin Fassnacht, Felix Beuschlein, Andrzej Januszewicz, Gabriele Siegert, Heinz Reichmann
JournalAnnals of clinical biochemistry (Ann Clin Biochem) Vol. 51 Issue Pt 1 Pg. 38-46 (Jan 2014) ISSN: 1758-1001 [Electronic] England
PMID23873873 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Normetanephrine
  • Levodopa
  • Metanephrine
  • 3-methoxytyramine
  • Dopamine
  • Norepinephrine
  • Epinephrine
Topics
  • Aged
  • Aged, 80 and over
  • Chromatography, Liquid
  • Dopamine (analogs & derivatives, blood, urine)
  • Epinephrine (blood, urine)
  • Female
  • Humans
  • Levodopa (administration & dosage, adverse effects)
  • Male
  • Metanephrine (blood, urine)
  • Middle Aged
  • Norepinephrine (blood, urine)
  • Normetanephrine (blood, urine)
  • Paraganglioma (blood, diagnosis, pathology, urine)
  • Parkinson Disease (blood, drug therapy, urine)
  • Pheochromocytoma (blood, diagnosis, pathology, urine)
  • Tandem Mass Spectrometry

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: